| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Triple Negative Breast Neoplasms | 23 | 2024 | 137 | 6.020 |
Why?
|
| Breast Neoplasms | 59 | 2024 | 2903 | 5.260 |
Why?
|
| Neoadjuvant Therapy | 26 | 2024 | 318 | 2.870 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 34 | 2024 | 2438 | 2.390 |
Why?
|
| Receptor, ErbB-2 | 26 | 2024 | 223 | 2.320 |
Why?
|
| Antibodies, Monoclonal, Humanized | 12 | 2021 | 930 | 1.690 |
Why?
|
| Programmed Cell Death 1 Receptor | 3 | 2020 | 159 | 1.380 |
Why?
|
| Biomarkers, Tumor | 19 | 2023 | 1464 | 1.330 |
Why?
|
| B7-H1 Antigen | 6 | 2023 | 250 | 1.250 |
Why?
|
| Receptors, Estrogen | 11 | 2024 | 384 | 1.240 |
Why?
|
| Antineoplastic Agents, Immunological | 4 | 2023 | 185 | 1.060 |
Why?
|
| Antineoplastic Agents | 9 | 2022 | 2360 | 1.030 |
Why?
|
| Receptors, Progesterone | 7 | 2021 | 167 | 1.020 |
Why?
|
| Female | 80 | 2024 | 44550 | 0.930 |
Why?
|
| Trastuzumab | 14 | 2024 | 68 | 0.790 |
Why?
|
| Humans | 91 | 2024 | 86678 | 0.740 |
Why?
|
| Paclitaxel | 11 | 2024 | 460 | 0.710 |
Why?
|
| Genes, BRCA1 | 3 | 2011 | 192 | 0.670 |
Why?
|
| Age Factors | 1 | 2023 | 1852 | 0.640 |
Why?
|
| Immunotherapy | 5 | 2022 | 629 | 0.640 |
Why?
|
| Neoplasm Staging | 14 | 2023 | 1939 | 0.620 |
Why?
|
| Precision Medicine | 7 | 2023 | 395 | 0.610 |
Why?
|
| Pharmacogenetics | 5 | 2019 | 434 | 0.600 |
Why?
|
| Circulating Tumor DNA | 3 | 2023 | 37 | 0.600 |
Why?
|
| Capecitabine | 4 | 2024 | 96 | 0.580 |
Why?
|
| Middle Aged | 47 | 2023 | 25040 | 0.570 |
Why?
|
| Receptors, Androgen | 3 | 2024 | 113 | 0.550 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2024 | 1313 | 0.550 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 5 | 2021 | 72 | 0.550 |
Why?
|
| Antimetabolites, Antineoplastic | 4 | 2021 | 236 | 0.490 |
Why?
|
| Adult | 39 | 2023 | 25659 | 0.480 |
Why?
|
| Clinical Decision-Making | 5 | 2021 | 257 | 0.470 |
Why?
|
| Tumor Microenvironment | 4 | 2022 | 418 | 0.460 |
Why?
|
| Disease-Free Survival | 8 | 2023 | 1204 | 0.440 |
Why?
|
| Aged | 33 | 2021 | 18423 | 0.420 |
Why?
|
| Quinazolines | 5 | 2023 | 220 | 0.410 |
Why?
|
| Genes, erbB-2 | 2 | 2009 | 24 | 0.390 |
Why?
|
| Breast | 7 | 2023 | 288 | 0.390 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 3 | 2023 | 56 | 0.390 |
Why?
|
| Piperazines | 3 | 2021 | 272 | 0.380 |
Why?
|
| Antibodies, Monoclonal | 4 | 2021 | 1376 | 0.370 |
Why?
|
| Neoplasm Metastasis | 13 | 2020 | 1056 | 0.350 |
Why?
|
| Mastectomy | 3 | 2018 | 243 | 0.340 |
Why?
|
| Drug Prescriptions | 3 | 2019 | 141 | 0.330 |
Why?
|
| Neoplasms | 5 | 2021 | 2898 | 0.320 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2020 | 70 | 0.310 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2021 | 150 | 0.290 |
Why?
|
| Prognosis | 10 | 2023 | 3680 | 0.290 |
Why?
|
| Treatment Outcome | 14 | 2023 | 7998 | 0.290 |
Why?
|
| Clinical Trials as Topic | 3 | 2022 | 1169 | 0.280 |
Why?
|
| Gene Expression Profiling | 6 | 2021 | 1384 | 0.280 |
Why?
|
| Cohort Studies | 6 | 2023 | 2768 | 0.280 |
Why?
|
| Carboplatin | 2 | 2017 | 286 | 0.270 |
Why?
|
| Benzimidazoles | 2 | 2017 | 140 | 0.270 |
Why?
|
| DNA Methylation | 5 | 2022 | 628 | 0.260 |
Why?
|
| Hormones | 2 | 2023 | 141 | 0.260 |
Why?
|
| Maytansine | 2 | 2021 | 9 | 0.250 |
Why?
|
| Molecular Targeted Therapy | 4 | 2021 | 266 | 0.250 |
Why?
|
| Genes, BRCA2 | 1 | 2005 | 160 | 0.250 |
Why?
|
| Aged, 80 and over | 13 | 2021 | 6513 | 0.250 |
Why?
|
| Phthalazines | 2 | 2021 | 39 | 0.240 |
Why?
|
| Survival Rate | 4 | 2021 | 1864 | 0.230 |
Why?
|
| Sirolimus | 3 | 2014 | 170 | 0.230 |
Why?
|
| Genetic Testing | 2 | 2018 | 535 | 0.230 |
Why?
|
| Yoga | 1 | 2023 | 5 | 0.230 |
Why?
|
| Meditation | 1 | 2023 | 5 | 0.230 |
Why?
|
| Pharmacogenomic Testing | 3 | 2019 | 97 | 0.220 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2022 | 54 | 0.220 |
Why?
|
| Anthracyclines | 1 | 2022 | 37 | 0.220 |
Why?
|
| Complementary Therapies | 1 | 2023 | 54 | 0.210 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2024 | 557 | 0.210 |
Why?
|
| Immunoconjugates | 1 | 2022 | 106 | 0.210 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2023 | 71 | 0.200 |
Why?
|
| Phenylthiohydantoin | 2 | 2019 | 41 | 0.200 |
Why?
|
| Electron Transport Complex I | 1 | 2021 | 28 | 0.200 |
Why?
|
| Benzamides | 3 | 2019 | 229 | 0.190 |
Why?
|
| Specimen Handling | 1 | 2021 | 98 | 0.190 |
Why?
|
| Telemedicine | 1 | 2023 | 169 | 0.190 |
Why?
|
| Brain Neoplasms | 2 | 2018 | 763 | 0.190 |
Why?
|
| Homologous Recombination | 1 | 2020 | 51 | 0.190 |
Why?
|
| Germ-Line Mutation | 4 | 2020 | 329 | 0.180 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2020 | 40 | 0.180 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2020 | 199 | 0.180 |
Why?
|
| Point-of-Care Systems | 2 | 2019 | 141 | 0.180 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2017 | 103 | 0.180 |
Why?
|
| Retrospective Studies | 7 | 2023 | 8496 | 0.170 |
Why?
|
| Imidazoles | 2 | 2019 | 162 | 0.170 |
Why?
|
| Pyridines | 1 | 2021 | 310 | 0.170 |
Why?
|
| Ovarian Neoplasms | 1 | 2005 | 744 | 0.170 |
Why?
|
| Prescription Drugs | 1 | 2019 | 36 | 0.170 |
Why?
|
| Mutation | 8 | 2023 | 3968 | 0.170 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2018 | 35 | 0.160 |
Why?
|
| CTLA-4 Antigen | 1 | 2018 | 135 | 0.160 |
Why?
|
| Combined Modality Therapy | 5 | 2023 | 1686 | 0.160 |
Why?
|
| Radiosurgery | 1 | 2021 | 272 | 0.160 |
Why?
|
| Albumins | 2 | 2015 | 133 | 0.150 |
Why?
|
| Carcinoma, Ductal, Breast | 3 | 2014 | 157 | 0.150 |
Why?
|
| Medical Order Entry Systems | 1 | 2017 | 25 | 0.150 |
Why?
|
| BRCA1 Protein | 2 | 2017 | 200 | 0.150 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2023 | 468 | 0.150 |
Why?
|
| Neoplasm, Residual | 3 | 2023 | 162 | 0.150 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2017 | 128 | 0.150 |
Why?
|
| Practice Guidelines as Topic | 2 | 2021 | 1037 | 0.140 |
Why?
|
| Dasatinib | 1 | 2016 | 37 | 0.140 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2022 | 3362 | 0.140 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2016 | 68 | 0.140 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2019 | 589 | 0.140 |
Why?
|
| Diphosphonates | 1 | 2016 | 36 | 0.140 |
Why?
|
| BRCA2 Protein | 1 | 2017 | 158 | 0.140 |
Why?
|
| DNA, Neoplasm | 1 | 2016 | 265 | 0.140 |
Why?
|
| Bone Density Conservation Agents | 1 | 2016 | 45 | 0.140 |
Why?
|
| Quinolines | 1 | 2016 | 95 | 0.130 |
Why?
|
| Physician's Role | 1 | 2017 | 179 | 0.130 |
Why?
|
| Meningeal Carcinomatosis | 1 | 2015 | 5 | 0.130 |
Why?
|
| Physician-Patient Relations | 2 | 2019 | 610 | 0.130 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2021 | 1204 | 0.130 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2014 | 407 | 0.130 |
Why?
|
| Meningeal Neoplasms | 1 | 2015 | 61 | 0.130 |
Why?
|
| Mifepristone | 1 | 2014 | 33 | 0.120 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2015 | 138 | 0.120 |
Why?
|
| Esophagitis | 1 | 2014 | 43 | 0.120 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2014 | 95 | 0.120 |
Why?
|
| Genome, Human | 1 | 2019 | 756 | 0.120 |
Why?
|
| Disease Progression | 4 | 2023 | 1532 | 0.120 |
Why?
|
| Genomics | 2 | 2017 | 720 | 0.120 |
Why?
|
| Nanoparticles | 1 | 2015 | 157 | 0.120 |
Why?
|
| Bayes Theorem | 3 | 2024 | 361 | 0.120 |
Why?
|
| Camptothecin | 1 | 2014 | 189 | 0.120 |
Why?
|
| Bone Neoplasms | 1 | 2016 | 322 | 0.120 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2017 | 1197 | 0.120 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2014 | 120 | 0.110 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2014 | 689 | 0.110 |
Why?
|
| Young Adult | 6 | 2021 | 5980 | 0.110 |
Why?
|
| Radiation Injuries | 1 | 2014 | 156 | 0.110 |
Why?
|
| Proportional Hazards Models | 3 | 2020 | 860 | 0.110 |
Why?
|
| Nitriles | 3 | 2019 | 149 | 0.110 |
Why?
|
| Carcinoma in Situ | 1 | 2012 | 53 | 0.110 |
Why?
|
| Healthcare Disparities | 3 | 2023 | 372 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 584 | 0.100 |
Why?
|
| Predictive Value of Tests | 4 | 2021 | 1673 | 0.090 |
Why?
|
| ErbB Receptors | 2 | 2011 | 485 | 0.090 |
Why?
|
| Macrophages | 1 | 2013 | 557 | 0.090 |
Why?
|
| Prospective Studies | 4 | 2020 | 4214 | 0.090 |
Why?
|
| Promoter Regions, Genetic | 3 | 2007 | 937 | 0.090 |
Why?
|
| Guidelines as Topic | 2 | 2021 | 162 | 0.080 |
Why?
|
| Doxorubicin | 2 | 2020 | 295 | 0.080 |
Why?
|
| United States | 4 | 2021 | 6681 | 0.080 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2011 | 311 | 0.080 |
Why?
|
| Logistic Models | 2 | 2016 | 1188 | 0.080 |
Why?
|
| Fanconi Anemia Complementation Group F Protein | 1 | 2007 | 6 | 0.080 |
Why?
|
| Follow-Up Studies | 3 | 2021 | 3642 | 0.080 |
Why?
|
| Transcriptome | 2 | 2023 | 580 | 0.080 |
Why?
|
| Maximum Tolerated Dose | 2 | 2021 | 270 | 0.070 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2007 | 165 | 0.070 |
Why?
|
| Animals | 3 | 2022 | 26590 | 0.070 |
Why?
|
| Estrogen Receptor alpha | 1 | 2007 | 144 | 0.070 |
Why?
|
| Epigenesis, Genetic | 3 | 2022 | 481 | 0.070 |
Why?
|
| Genes, Neoplasm | 1 | 2006 | 37 | 0.070 |
Why?
|
| Patient Selection | 2 | 2021 | 686 | 0.070 |
Why?
|
| Aneuploidy | 1 | 2005 | 55 | 0.070 |
Why?
|
| Disease Management | 2 | 2019 | 327 | 0.070 |
Why?
|
| Survival Analysis | 3 | 2018 | 1538 | 0.070 |
Why?
|
| Male | 8 | 2023 | 40988 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2005 | 110 | 0.070 |
Why?
|
| Conserved Sequence | 1 | 2006 | 210 | 0.070 |
Why?
|
| Probability | 1 | 2005 | 355 | 0.060 |
Why?
|
| Immunohistochemistry | 3 | 2018 | 1753 | 0.060 |
Why?
|
| Receptor, TIE-2 | 1 | 2024 | 15 | 0.060 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2007 | 592 | 0.060 |
Why?
|
| Personal Satisfaction | 1 | 2023 | 62 | 0.060 |
Why?
|
| Liquid Biopsy | 1 | 2023 | 33 | 0.060 |
Why?
|
| Biology | 1 | 2023 | 50 | 0.060 |
Why?
|
| Carcinoma, Lobular | 2 | 2014 | 81 | 0.060 |
Why?
|
| Biopsy | 2 | 2017 | 1163 | 0.050 |
Why?
|
| Demography | 1 | 2023 | 177 | 0.050 |
Why?
|
| Methylation | 1 | 2023 | 251 | 0.050 |
Why?
|
| Models, Statistical | 1 | 2005 | 575 | 0.050 |
Why?
|
| Risk Factors | 2 | 2018 | 5420 | 0.050 |
Why?
|
| Amenorrhea | 1 | 2021 | 27 | 0.050 |
Why?
|
| Time Factors | 2 | 2021 | 5214 | 0.050 |
Why?
|
| Data Accuracy | 1 | 2021 | 31 | 0.050 |
Why?
|
| Drug Discovery | 2 | 2015 | 103 | 0.050 |
Why?
|
| United States Food and Drug Administration | 1 | 2021 | 127 | 0.050 |
Why?
|
| Bridged-Ring Compounds | 1 | 2020 | 13 | 0.050 |
Why?
|
| Ferredoxin-NADP Reductase | 1 | 2020 | 15 | 0.050 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2020 | 26 | 0.050 |
Why?
|
| Oxazepines | 1 | 2019 | 4 | 0.050 |
Why?
|
| Patient Satisfaction | 1 | 2023 | 455 | 0.050 |
Why?
|
| Taxoids | 1 | 2020 | 129 | 0.050 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2019 | 18 | 0.050 |
Why?
|
| Longitudinal Studies | 1 | 2023 | 1019 | 0.050 |
Why?
|
| Cyclophosphamide | 1 | 2020 | 299 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2021 | 526 | 0.040 |
Why?
|
| Postmenopause | 1 | 2020 | 98 | 0.040 |
Why?
|
| Kinetics | 1 | 2022 | 1513 | 0.040 |
Why?
|
| Drug Recalls | 1 | 2019 | 13 | 0.040 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2019 | 26 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 2 | 2014 | 552 | 0.040 |
Why?
|
| Receptors, Steroid | 1 | 2019 | 42 | 0.040 |
Why?
|
| Bevacizumab | 1 | 2020 | 281 | 0.040 |
Why?
|
| Everolimus | 1 | 2018 | 40 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 456 | 0.040 |
Why?
|
| Europe | 1 | 2019 | 309 | 0.040 |
Why?
|
| Genotyping Techniques | 1 | 2018 | 68 | 0.040 |
Why?
|
| Research | 1 | 2019 | 253 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2021 | 573 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2019 | 322 | 0.040 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2017 | 22 | 0.040 |
Why?
|
| Pandemics | 1 | 2023 | 740 | 0.040 |
Why?
|
| Drug Labeling | 1 | 2017 | 41 | 0.040 |
Why?
|
| DNA Copy Number Variations | 1 | 2018 | 171 | 0.040 |
Why?
|
| California | 1 | 2017 | 138 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2021 | 1961 | 0.040 |
Why?
|
| Contrast Media | 1 | 2022 | 1078 | 0.040 |
Why?
|
| CpG Islands | 2 | 2007 | 151 | 0.040 |
Why?
|
| Health Personnel | 1 | 2019 | 202 | 0.040 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2016 | 78 | 0.040 |
Why?
|
| Social Perception | 1 | 2017 | 95 | 0.040 |
Why?
|
| src-Family Kinases | 1 | 2016 | 75 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2016 | 2426 | 0.030 |
Why?
|
| Azacitidine | 2 | 2006 | 137 | 0.030 |
Why?
|
| Attitude to Health | 1 | 2017 | 220 | 0.030 |
Why?
|
| Vertical Dimension | 1 | 1995 | 1 | 0.030 |
Why?
|
| Orthodontics, Corrective | 1 | 1995 | 3 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 861 | 0.030 |
Why?
|
| Malocclusion | 1 | 1995 | 6 | 0.030 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2015 | 4 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2017 | 677 | 0.030 |
Why?
|
| Genotype | 1 | 2020 | 1852 | 0.030 |
Why?
|
| Communication | 1 | 2019 | 442 | 0.030 |
Why?
|
| Retreatment | 1 | 2015 | 107 | 0.030 |
Why?
|
| Cell Count | 1 | 2015 | 195 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 380 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 2013 | 912 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2006 | 2262 | 0.030 |
Why?
|
| Alleles | 1 | 2017 | 1128 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2021 | 2264 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2014 | 295 | 0.030 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2013 | 21 | 0.030 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2013 | 33 | 0.030 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2013 | 44 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 329 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 426 | 0.030 |
Why?
|
| Dexamethasone | 1 | 2014 | 326 | 0.030 |
Why?
|
| Triazoles | 1 | 2013 | 96 | 0.030 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2013 | 114 | 0.030 |
Why?
|
| Chemoradiotherapy | 1 | 2015 | 301 | 0.030 |
Why?
|
| Induction Chemotherapy | 1 | 2013 | 147 | 0.030 |
Why?
|
| Quality of Life | 1 | 2020 | 1585 | 0.030 |
Why?
|
| Extracellular Matrix | 1 | 2013 | 232 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2020 | 2357 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 357 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 916 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2013 | 486 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 2504 | 0.020 |
Why?
|
| Neuroblastoma | 1 | 2014 | 375 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2013 | 715 | 0.020 |
Why?
|
| DNA-Binding Proteins | 2 | 2006 | 1208 | 0.020 |
Why?
|
| Adolescent | 2 | 2020 | 8984 | 0.020 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2014 | 386 | 0.020 |
Why?
|
| Senegal | 1 | 2009 | 4 | 0.020 |
Why?
|
| Nigeria | 1 | 2009 | 152 | 0.020 |
Why?
|
| Health Surveys | 1 | 2009 | 239 | 0.020 |
Why?
|
| Transcription Factors | 2 | 2006 | 1565 | 0.020 |
Why?
|
| Apoptosis | 1 | 2015 | 1683 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2013 | 1992 | 0.020 |
Why?
|
| Liver Neoplasms | 1 | 2014 | 738 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2008 | 476 | 0.020 |
Why?
|
| Cyclin A1 | 1 | 2006 | 2 | 0.020 |
Why?
|
| Cathepsin K | 1 | 2006 | 3 | 0.020 |
Why?
|
| MSX1 Transcription Factor | 1 | 2006 | 3 | 0.020 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2006 | 12 | 0.020 |
Why?
|
| Cyclin A | 1 | 2006 | 28 | 0.020 |
Why?
|
| Cathepsins | 1 | 2006 | 21 | 0.020 |
Why?
|
| DNA Modification Methylases | 1 | 2006 | 25 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2013 | 1195 | 0.020 |
Why?
|
| DNA Repair | 1 | 2008 | 356 | 0.020 |
Why?
|
| Keratin-5 | 1 | 2006 | 3 | 0.020 |
Why?
|
| Keratin-6 | 1 | 2006 | 3 | 0.020 |
Why?
|
| Keratins | 1 | 2006 | 63 | 0.020 |
Why?
|
| Vimentin | 1 | 2006 | 44 | 0.020 |
Why?
|
| Neprilysin | 1 | 2006 | 42 | 0.020 |
Why?
|
| Hydroxamic Acids | 1 | 2005 | 49 | 0.020 |
Why?
|
| Sample Size | 1 | 2006 | 130 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 879 | 0.020 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2006 | 157 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2006 | 369 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2005 | 207 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2006 | 1041 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2006 | 255 | 0.020 |
Why?
|
| Muscle, Smooth | 1 | 2006 | 354 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2006 | 279 | 0.010 |
Why?
|
| Lymphocytes | 1 | 2005 | 464 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2006 | 429 | 0.010 |
Why?
|
| Actins | 1 | 2006 | 451 | 0.010 |
Why?
|
| Research Design | 1 | 2006 | 594 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 2006 | 558 | 0.010 |
Why?
|
| Gene Expression | 1 | 2005 | 1284 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2005 | 1981 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2006 | 2706 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2006 | 1077 | 0.010 |
Why?
|
| Phenotype | 1 | 2006 | 2380 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 2006 | 1169 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2006 | 2271 | 0.010 |
Why?
|
| Malocclusion, Angle Class I | 1 | 1995 | 1 | 0.010 |
Why?
|
| Malocclusion, Angle Class II | 1 | 1995 | 1 | 0.010 |
Why?
|
| Mesial Movement of Teeth | 1 | 1995 | 1 | 0.010 |
Why?
|
| Incisor | 1 | 1995 | 7 | 0.010 |
Why?
|
| Tooth Extraction | 1 | 1995 | 10 | 0.010 |
Why?
|
| Cephalometry | 1 | 1995 | 50 | 0.010 |
Why?
|
| Molar | 1 | 1995 | 21 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2006 | 1721 | 0.010 |
Why?
|
| Child | 1 | 1995 | 6928 | 0.000 |
Why?
|